Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1994-5-19
|
pubmed:abstractText |
The pharmacokinetics of intranasal, an intravenous infusion, and intramuscular glucagon has been studied in 5 healthy subjects and 11 patients with insulin-dependent diabetes mellitus. After infusion the elimination half-life was significantly longer in diabetics (11.9 vs 6.6 min) and the apparent volume of distribution was twice as high in diabetics (0.19 vs 0.37 l.kg-1). The metabolic clearance rates were the same in the two groups (18.9 and 21.3 ml.min-1.kg-1 in controls and in diabetics) and were about twice those previously reported. After 1 mg intranasally the Cmax of immunoreactive glucagon (IRG) was similar in diabetic and in healthy subjects. Administration of a higher dose (2 mg) to diabetic patients produced a higher plasma level, although not proportionately so. The AUC after 1 mg was also similar in controls and in diabetics. The elimination half-life in both groups was similar to the value found after i.v. infusion; it was significantly shorter in controls (5.5 min) than in diabetics (13.8 min). In both groups, mean Cmax was significantly lower than after IM glucagon, the relative bioavailability of 1 mg intranasally vs IM injection being less than 30%. After IM administration, the Cmax and AUC of IRG in controls and in diabetic patients, were identical. The apparent elimination half-life was also similar in the two groups, and was three- to four-times longer (28.6 and 31.4 min) than after infusion or intranasal administration, possibly because estimation of the t1/2 was affected by slow release of the hormone from the site of injection.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0031-6970
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
555-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8157042-Administration, Intranasal,
pubmed-meshheading:8157042-Adult,
pubmed-meshheading:8157042-Diabetes Mellitus, Type 1,
pubmed-meshheading:8157042-Glucagon,
pubmed-meshheading:8157042-Half-Life,
pubmed-meshheading:8157042-Humans,
pubmed-meshheading:8157042-Infusions, Intravenous,
pubmed-meshheading:8157042-Injections, Intramuscular
|
pubmed:year |
1993
|
pubmed:articleTitle |
Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients.
|
pubmed:affiliation |
Istituto Scientifico San Raffaele, Università degli Studi, Milano, Italy.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|